"I am too damn old to fight windmills." I'm not.

New Post Public Reply Private Reply Replies (0) Message Board
USS JOHNSTON Cycl2R #122182
729
"I am too damn old to fight windmills."

I'm not. Regardless, we're not fighting imaginary windmills. By choosing a non-China partner, we're choosing not to lose our intellectual property (Leronlimab) without legal recourse. I agree 100% American BP's have a horrible track record of off-shoring and abusing their patients and any number of other crimes. The difference is - and it' huge - an American BP can be sued. They will pay billions in lawsuits if they lose, e.g., as Pfizer did about 12 years go.

But China? Will anyone bring the CCP to court if they manufacture LL at a huge discount and put Cytodyn out of business? We have little to no legal recourse in a communist dictatorship. And what happens if China invades Taiwan - will never happen, I know - but if it did happen, would we (and much of the world) likely boycott many/all Chinese products for years? What happens to CYDY SP if the world is boycotting our China-based partner?

Bottom line, we've seen too much, come too far, and waited too long to risk everything by choosing a partner in a lawless regime. I hate BP's as much as anyone, but we have little to no legal recourse with CCP BP's.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

How Aon Has Thrived: A 10-Year Investment Journey

Updated Category News Views 132

A Decade of Growth for Aon Aon has shown remarkable performance over the last ten years, significantly surpassing overall market growth with an impressive annualized return of 15.51%. As of now, Aon's market capitalization stands strong at $80.39 billion, reflecting its solid position in the industry. The Power of a $1000 Investment If an investor had taken the leap and...

Continue Reading
Bioretec Adjusts Financial Projections Amid Strategic Review

Updated Category News Views 179

Bioretec's Revised Financial Outlook Bioretec Ltd, a leading innovator in the medical device sector, is undergoing a significant reevaluation of its financial targets. This decision stems from the company's ongoing review of its commercialization strategy, particularly in the context of its flagship product, the DrillPin. Initially announced in September 2025, the company...

Continue Reading
Crowne Plaza by IHG: Redefining Travel for Modern Professionals

Updated Category News Views 274

Redefining the Travel Experience with Crowne Plaza by IHG Crowne Plaza by IHG continues to innovate, creating thoughtfully designed spaces and experiences that foster connections, making it a top choice for hybrid travelers. Crowne Plaza has released a comprehensive white paper on blended travel, showcasing significant developments in the hospitality sector tailored for a...

Continue Reading
Ensign Group Expands Operations With Key Acquisitions

Updated Category News Views 158

Ensign Group Expands Operations in Iowa Based in San Juan Capistrano, California, The Ensign Group, Inc. (Nasdaq: ENSG) is making large strides in its expansion efforts. Recently, the company announced its acquisition of Crystal Heights Care Center, a skilled nursing facility with 72 beds located in Oskaloosa, Iowa. This acquisition represents a significant step for...

Continue Reading
Galaxy Digital Partners with Superstate for Innovative Tokenization

Updated Category News Views 201

Galaxy Digital Teams Up with Superstate for Tokenization Galaxy Digital Inc. (Nasdaq: GLXY) has made headlines by teaming up with Superstate to break new ground in the financial sector. This groundbreaking partnership enables shareholders to tokenize and manage GLXY shares directly on a major blockchain, specifically the Solana platform. With this, Galaxy becomes the...

Continue Reading